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Abstract
Background Brainstem gliomas (BSG) are relatively rare tu-
mors of which recurrent pediatric diffuse intrinsic pontine
gliomas (RPDIPG) comprise a distinct group. Numerous trials
have been conducted on RPDIPG, none of which have result-
ed in identifying any proven pharmacological treatment ben-
efit. This study included 40 patients diagnosed with different
types of BSG, but it was decided to describe first the encour-
aging results in the most challenging group of RPDIPG.
Materials and methods This single-arm phase II study evalu-
ated the efficacy and safety of the combination of
antineoplastons A10 and AS2-1 (ANP) in patients with
RPDIPG. Seventeen patients (median age 8.8 years) were
enrolled, and all were diagnosed with RPDIPG. ANP was
administered intravenously daily. Efficacy analyses were con-
ducted in this group of patients.
Results In this group, complete responses were observed in
6 % of patients, partial responses in 23.5 %, and stable disease
in 11.8 %. Six-month progression-free survival was 35.3 %.
One-year overall survival was 29.4 %, 2 years 11.8 %, and 5,
10, and 15 years 5.9 %. One patient with DIPG is alive over
15 years post-treatment. Grade 3 and higher toxicities includ-
ing hypokalemia and fatigue occurred in 6 %, hypernatremia
in 18 %, fatigue and urinary incontinence in 6 %, and somno-
lence in 12 %. In a single patient, grade 4 hypernatremia
occurred when he was on mechanical ventilation. He was
disconnected from the ventilator and died from brain tumor
according to the attending physician. Responding patients
experienced improved quality of life.
Conclusion The results suggest that ANP shows efficacy and
acceptable tolerability profile in patients with RPDIPG.
Keywords Antineoplastons A10 andAS2-1 . Brainstem
glioma . Diffuse intrinsic pontine glioma . Recurrent glioma .
Phase II clinical trial
Introduction
Brain tumors in children account for 20 % of all neoplasms
[1]. Brainstem gliomas are relatively rare tumors which con-
stitute 1.6 % of primary brain and CNS tumors by site [2]. In
children, high-grade gliomas—anaplastic astrocytomas (AA),
glioblastoma multiforme (GBM), and diffuse intrinsic pontine
gliomas (DIPG)—are the most aggressive neoplasms and the
leading causes of cancer-related mortality [1, 3, 4]. Based on
the most recent studies, pediatric DIPG forms a distinct group
which is characterized by recently identified mutations in the
histone H3.3 (H3F3A gene) [4]. Numerous clinical trials have
been carried out in patients with DIPG, but no pharmacolog-
ical agents have to date proven efficacious—leaving standard
radiation therapy (RT) as the mainstay of treatment [1, 3]. The
overall outlook is poor and nearly all children eventually die.
In most studies, the median survival time is shorter than 1 year
and less than 10 % of patients survive over 2 years [1].
Antineoplastons A10 and AS2-1 (ANP) are synthetic ami-
no acid derivatives. A10 is a formulation consisting of a 4:1
ratio of phenylacetylglutaminate sodium (PG) and
phenylacetylisoglutaminate sodium (isoPG). AS2-1 is a for-
mulation with a 4:1 ratio of phenylacetate sodium (PN) and
PG [5]. The proposed antineoplastic activity of ANP in glio-
mas is shown in Fig. 1 and consists of specific effects on the
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AKT2 and RAS pathways and tumor suppressor genes TP53
and p21 and on apoptosis [6–16].
Genome-wide analyses have been conducted to identify
recurrent amplifications of receptor tyrosine kinases (RTKs)
and cell cycle regulatory genes in DIPGs and indicated sub-
stantial tumor heterogeneity and involvement ofRAS and AKT
signaling pathways [17, 18]. Successful treatment of a hetero-
geneous tumor may require inhibitors that affect not only
multiple targets, but also multiple pathways, such as ANP.
Phase I studies of injections of antineoplastons A10 and
AS2-1 (ANP) as well as prior phase II studies included pedi-
atric patients [5, 19–22]. In two of these studies, complete
responses (CR) were observed in pediatric DIPG [5, 23]. In
our phase II study (BT-03) of ANP of 20 subjects with
astrocytomas, conducted in 1988, CR were documented in
two cases of DIPG in young adults [20, 21]. One of these
patients is currently surviving tumor free for over 25 years
after being treated with ANP for DIPG, which recurred after
radiation therapy. These positive preliminary data prompted
us to design and conduct a single-arm phase II study of ANP
to assess the efficacy and safety of this treatment in pediatric
patients diagnosed with recurrent DIPG (RPDIPG).
Patients and methods
Patient population
The protocol permitted admission of patients with brainstem
glioma for whom standard curative treatments are not avail-
able. A total of 40 patients were enrolled, but the scope of this
paper has been limited to the 17 RPDIPG patients.
Recruited patients were all over 4 years of age and had
radiologic evidence of brainstem glioma by gadolinium-
enhanced MRI performed 14 days prior to being enrolled in
the study. Based on MRI only, DIPG can be diagnosed if the
tumor has an epicenter in the pons and involves more than
50 % of the pons. Patients with neurofibromatosis are not
covered by this definition and were not included. The tumors
involving less than 50 % of the pons or exophytic were
classified as DIPG if they had anaplastic or GBM histology
[24–26].
Eligibility criteria included a Karnofsky Performance Sta-
tus (KPS) of 60–100. The subjects were required to have
relatively normal hematopoietic and hepatic function with
white blood cell count (WBC) over 1,500/mm3 and platelet
count over 50,000 mm3, no evidence of hepatic or renal
insufficiency, and a total bilirubin and serum creatinine of no
higher than 2.5 mg/dL. SGOTand SGPTwere to be no higher
than 5× the upper limits. At least 8 weeks must have elapsed
since the last dose of RT, and at least 4 weeks since the last
dose of chemotherapy (6 weeks for nitrosoureas), or immu-
notherapy. The use of corticosteroids was permitted to reduce
symptoms and signs attributed to cerebral edema, but it was
recommended that the smallest doses compatible with the
preservation of optimal neurologic function be used. Confir-
mation of the pathologic diagnosis by an outside pathologist
was also required.
The exclusion criteria included serious active infection,
fever, or other serious concomitant disease that would
interfere with the evaluation of the treatment (e.g., severe
heart or lung disease). There were no exclusion criteria
based on tumor size, multifocality, or leptomeningeal
involvement.
All study subjects and/or guardians read, understood, and
signed written informed consent prior to enrollment. This
study was conducted in accordance with the US Code of
Federal Regulations, Title 21, Parts 11, 50, 56, and 312; the
Declaration of Helsinki (1964) including all amendments and
revisions; the Good Clinical Practices: Consolidated Guide-
line (E6); International Conference on Harmonization; and the
FDA’s Guidance for Industry. The study was sponsored by the
Burzynski Research Institute (BRI) and conducted by the
Burzynski Clinic (BC) in Houston, TX. The patients did not
pay for the investigational agents.
Study design
The study was designed as a single-arm, two-stage, phase II
trial of ANP as monotherapy. The study was listed by the
National Cancer Institute (NCT00003459). It was supervised
by an independent Institutional Review Board (BRI-IRB, BC-
BT-11).
The study was performed according to Protocol BT-11
which was submitted to the FDA under the IND 43,742.
Subsequently, the protocol was amended by BRI several
times; however, none of the amendments altered the aim or
design of the original study objectives/outcomes.
Statistical considerations
Sample size
The sample size was calculated based upon the previously
usedmethod described by Chang et al. [27]. A response rate to
ANP of ≥10 % was considered “of interest,” and the primary
endpoint was to determine the overall response rate which was
confirmed CR or partial response (PR) to ANP therapy. Ob-
jective response (OR) and progression-free survival (PFS)
were measured from the first day of ANP administration.
The distributions of survival and treatment failure were esti-
mated by Kaplan-Meier analysis. As mentioned before, this
paper described 17 RPDIPG patients out of the total of 40
brainstem glioma patients.
2052 Childs Nerv Syst (2014) 30:2051–2061
Treatment
The median maximum dose of ANP A10 was 8.14 g/kg/day
(5.69–15.87) and for AS2-1 0.42 g/kg/day (0.21–0.58). The
duration of IVANP therapy ranged from 5 to 178 weeks with
a median of 61 weeks.
ANP A10 and AS2-1 were delivered via a dual-channel
infusion pump and single-lumen subclavian catheter (Broviac
or Groshong) every 4 h. On the first day of administration of
ANP, the flow rate of the pump was maintained at 25 mL/h.
Beginning from the second day, individual injections were
given at 100 to 250 mL/h depending on the patient’s age and
tolerance.
Approximate guidelines for flow rates are provided.
1. Four to 7 years old—flow rate 100 mL/h
2. Seven to 10 years old—flow rate 150 mL/h
3. Ten to 16 years old—flow rate 200 mL/h
4. Sixteen to 18 years old—flow rate 250 mL/h
On the first day of treatment, the pump was loaded with
60 mL of A10 (0.3 g/mL) and 60 mL of AS2-1 (0.08 g/mL).
The volume of each injection was 10 mL administered every
4 h, six times a day. Beginning from the second day of
treatment in children younger than 12 years of age, the dose
of each injection was increased on a daily basis in increments
of 10 mL until the highest tolerable dose or effective dose was
reached. For children 12 years of age or older, the dose of A10
was escalated in increments of 20 mL daily, and over 16 years
of age, in increments of 40 mL. When the study subject
reached the highest tolerated dose, the “escalation phase” of
the treatment stopped.
In summary, there were three different volumes of daily
dosage increments of ANP depending on the patient’s age:
10 mL daily dose increase per injection for children younger
than 12 years of age, 20 mL for children between 12 and
15 years of age, and 40 mL for patients over 16 years of age.
The complicated part of the regimen, which is escalation of
dosage, was finished during the patient’s treatment at BC
under careful supervision of the sub-investigator assigned to
the case. Upon returning home, the patient is given a regimen
that consisted of administration of the fixed dose (volume) of
ANP through an automatic pump six times a day. The pump
was typically loaded with ANP once a day and the rest of the
administration was done automatically. It was possible to
disconnect the pump in between IV boluses given every 4 h
to permit patient’s physical activities. The single dosing could
be completed within 1 h which would leave 3 h until the next
dose, and during this time, the pump could be disconnected.
Long-term observation of the patients confirmed that the
regimen created a limited burden on the quality of life. After
symptomatic improvement, the children were able to attend
school and graduate from it. The subject continued the daily
administration of six doses of A10 and AS2-1 (every 4 h via
Fig. 1 Proposed mechanism of
action of antineoplastons A10 and
AS2-1. The ingredients of
antineoplastons A10 and AS2-1,
PN and PG, affect signal
transmission through AKT and
RAS pathways, promote
apoptosis, and interrupt cell cycle
progression at G1/S and G2/M
checkpoints
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an automated pump) until a response to the treatment was
determined.
The rationale for using two formulations of ANP was based
on prior clinical trials, pharmacokinetic studies, and laboratory
research [5]. The escalation of the dosage of ANP was recom-
mended based on the positive results of previous studies carried
out to determine whether patients were able to tolerate large
volume infusions of intravenous fluids associated with higher
doses of ANP [5]. As a safety precaution, it was recommended
that the escalation of the dosages would continue through phase
II and phase III trial programs.
Medications that were considered necessary for the pa-
tients’ welfare and that did not interfere with the evaluation
of treatment were given at the discretion of the investigator.
The use of corticosteroids was carefully monitored. Treatment
with other antineoplastic or immunomodulatory agents was
not permitted during the study. Subjects received full support-
ive care, including transfusions of blood products and antibi-
otics when appropriate.
The initial 3 weeks of therapy was administered by BC
staff on an outpatient basis, in Houston, TX. The treatment did
not require hospitalization. Subjects and/or their legal guard-
ians were trained by clinic staff to self-administer ANP ther-
apy during this time. Starting on week 4, ANP therapy was
administered at home with 24-h support available via phone.
Treatment and monitoring of the subject’s condition, once
released to self-administered therapy, continued under the
supervision of the subject’s local attending physician (physi-
cian who signed the FDA form 1572).
Evaluation and follow-up
Prior to the start of treatment, a gadolinium-enhanced MRI
measured all contrast-enhancing lesions. The products of the
two greatest perpendicular diameters of all lesions were calcu-
lated and totaled, providing a baseline evaluation for each study
subject. The tumor measurements were based on contrast-
enhanced lesions, but the nonenhancing lesion and overall
tumor size were also measured including T2 and FLAIR im-
ages [26, 28]. CR required the disappearance of all enhancing
lesions sustained for at least 4 weeks, with only physiologic
replacement doses of steroids acceptable. Positron emission
tomography (PET) shows resolution of hypermetabolic lesions.
PR required 25 % or higher decrease of the sum of the products
of the two largest perpendicular diameters of enhancing lesions
and stable or reduced corticosteroid doses. PD was determined
when there was over 25% increase of enhancing lesions or new
lesions, and stable disease (SD) was the status between PR and
PD. In the case of SD, the duration was measured from the time
therapy commenced. The results of all MRI and PET scans
were verified by radiologists not affiliated with BRI or BC, and
their determination of response was accepted. Complete and
partial responses were verified by central radiology review.
Blood and urine tests (complete blood count with differential,
platelet count, reticulocyte count, and serum chemistry), anti-
convulsant serum levels, prothrombin time, and partial throm-
boplastin timewere carried out on all subjects prior to the start of
treatment to establish baseline values. The additional pretreat-
ment measurements included KPS, vital signs, clinical disease
status, demographics, medical history and current medications,
physical examination with neurologic emphasis, chest X-rays,
and EKG. Toxicity was evaluated in all patients enrolled in the
study. Data on adverse drug experiences (ADEs) were collected
during the initial 3 weeks of ANP therapy by clinic staff at the
BC. MRIs were repeated at least every 8 weeks during the first
2 years unless the patient’s condition or confirmation of re-
sponse required an MRI within 4 weeks. PET scans were












Astrocytoma, grade I 2
Karnofsky Performance Score
Median (%) BT / AT
70 / 80
60 6 / 4
70 5 / 2
80 5 / 6
90 0 / 1
100 1 / 2
Duration of symptoms prior to enrollment
Less than 6 months 18 %





CH + RT 53 %
SU + CH + RT 6 %
One-regimen CH 82 %
Two-regimen CH 0
Three-regimen CH 18 %
AT at the end of treatment, BT at treatment start, C Caucasian, CH
chemotherapy, DIPG diffuse intrinsic pontine glioma, H Hispanic, O
Oriental, RT radiation therapy, SU surgery
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performed as necessary. When study subjects transitioned to
home-based therapy administration under the care of a local
physician, clinic staff made daily telephone contact for the first
2 months to ensure protocol compliance, to resolve any issues
with therapy administration, and to continue assessing ADEs.
Weekly contact wasmade starting in the thirdmonth. Continued
patient treatment with ANPwas determined on at least a weekly
basis and based upon the trial protocol, patient health status, and
the response to treatment.
The records of daily administration of ANP were main-
tained and carefully checked for drug accountability. The
ADEs were graded according to the Common Terminolo-
gy Criteria for Adverse Events (CTCAE v.3). Pharmaco-
kinetic studies have been previously carried out and were
not included in this study. Based on a prior study, there
was no indication of interference with essential supportive
medications, in particular, antiseizure drugs.
Results
Patient demographics
The enrollment of subjects diagnosed with RPDIPG com-
menced on March 13, 1996 and continued through
December 14, 2006. As of September 12, 2007, all sub-
jects were removed from the therapy, as a consequence of
either a CR, subject request, PD, or worsening clinical
condition.
Demographics for the subjects are summarized in Table 1.
Patient demographics did not change during the study and
were comparable to the other studies conducted on brainstem
glioma. The tumor measurements on MRI T2-weighted im-
ages determined from 61 to 100 % involvement of the pons
(median 85 %). There were one GBM and one AA as well
as two cases of pilocytic astrocytoma, grade 1 in this
group. The data on confirmation of diagnosis and tumor
recurrence, confirmation of response, and change in tu-
mor measurements during treatment are provided in
Table 2.
Efficacy
In the group of 17 RPDIPG patients, there were five cases of
OR (29.5 %): one CR (6 %) and 4 PR (23.5 %). An additional
group of two patients (11.8 %) had stabilization of their dis-
ease, eight patients (47 %) developed progressive disease, and
two cases (12 %) were nonevaluable (NE). Figures 2 and 3
illustrate the response to treatment with ANP in two patients.
Fig. 2 DIPG in a 10-year-old male (case 8) which recurred two times
after partial surgical resection.MRI of the head: 1—T1 nonenhanced, 2—
contrast-enhanced, 3—T2W, and 4—FLAIR images. PR was
documented by the MRI and CR was established by the normalization
of the follow-up PET scans. Arrows indicate tumors
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Survival data
The Kaplan-Meier OS and PFS curves are shown in Fig. 4.
Estimated overall survival at 10 and 15 years is 5.9 % up to July
2013. The survival is 29.4% at 1 year and 11.8% at 2 years. One
patient remains alive over 15 years from the start of treatment.
Safety and adverse events
Study population
Safety assessments were analyzed based upon the total num-
ber of enrolled patients (n=17). Grade 4 toxicities including
hypokalemia and fatigue occurred in 6 % and hypernatremia
in 18% of the group. Grade 3 fatigue and urinary incontinence
occurred in 6 % and somnolence in 12 %. In patient 2
(Table 2), grade 4 hypernatremia was detected when he was
on mechanical ventilation in the intensive care unit. This
patient received terminal care and was disconnected from
the ventilator upon request of the members of his family. His
attending physician determined brain tumor as the cause of
death. No chronic events occurred. Responding patients ex-
perienced improved quality of life. Brain tumor patients fre-
quently receive corticosteroids as part of their therapeutic
regimen to reduce cerebral edema around tumors. The use of
corticosteroids, the infusion of large volumes of sodium-
containing solutions during ANP therapy, and the brain tumor
itself predispose a patient to an increased incidence of serum
sodium and potassium concentration abnormalities. As a
Fig. 3 DIPG in a 7-year-old
female (case 9) which recurred
after radiation therapy and
chemotherapy with etoposide.
MRI of the head: 1—T1
nonenhanced, 2—contrast-
enhanced, and 3—T2W images.
MRI documented PR. Arrows
indicate tumors
















Fig. 4 The Kaplan-Meier survival curves from the start of treatment for
recurrent pediatric DIPG
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result, hypernatremia and hypokalemia were reported in a
substantial number of patients.
Discussion
Between 1984 and 2005, 29 studies in DIPG have been
reported and were reviewed by Hargrave et al. [1]. The
additional clinical trials were reviewed by us previously
[3, 29]. These trials did not demonstrate any improvement
in efficacy beyond standard radiation therapy which re-
mains the standard treatment. Less than 10 % of children
with a diagnosis of DIPG do not survive more than 2 years
from diagnosis, and very few live beyond 5 years. In recent
years, only seven trials were conducted for a mixed popu-
lation of pediatric patients, usually with high-grade glioma,
with a small percentage of patients diagnosed with DIPG
[30–36]. The results from this trial in comparison to other
comparable studies are presented in Table 3. Five trials were
conducted for recurrent brainstem glioma, usually at the
first relapse. The remaining two trials included children
with both recurrent as well as newly diagnosed brainstem
glioma. Lashford et al. reported data on treatment with RT
and temozolomide (TMZ) in 18 eligible patients diagnosed
with progressive diffuse intrinsic brainstem glioma with the
tumor centered in the pons in 15 subjects [30]. They report-
ed a PR of 6 %, SD of 17 %, and a median survival of
6.2 months. Dreyer et al. evaluated ten brainstem glioma
patients with recurrent or progressive disease after conven-
tional RTand chemotherapy [31]. These patients were treat-
ed with an analog of daunomycin, idarubicin. No OR was
reported, but there were one case of SD and seven cases of
PD among eight evaluable patients. Warren et al. used a
combination of lobradimil and carboplatin for brainstem
glioma at first relapse (12 patients) [32]. There was no OR
and the median time to progression was only 84 days.
Tipifarnib was used by Fouladi et al. in a phase II trial for
recurrent or progressive high-grade glioma including
brainstem glioma and PNET [33]. In 41 patients, there were
one PR and four cases of SD (11 %). Gururangan et al. used
a combination of bevacizumab and irinotecan in children
with recurrent DIPG [34]. In the population of 17 patients,
there was no OR, but five cases of SD and 13 PD. Median
PFS was 2.3 months and 6-month PFS was 9.7 %. Minturn
et al. used metronomic oral topotecan in nine children with
recurrent brainstem glioma. They reported SD in two pa-
tients, but no OR [35]. Warren et al. conducted a phase II
study with 06-benzylguanine and TMZ in 16 children with
recurrent or progressive brainstem gliomas [36]. No OR
was reported and 6-month PFS was zero. These trials failed
to prove efficacy for any of the treatment regimens under
evaluation and the treatments themselves were associated
with substantial toxicity.
The review of the literature indicates that there are substan-
tial differences in the definitions of DIPG and the evaluations
of the responses. In this study, we accepted the criteria used for
all COG and PBTC studies. DIPG are predominantly
nongadolinium enhancing, hyperintense on T2-weighted im-
ages and hypodense on T1. Despite this fact, all studies
conducted within the last 10 years used the Macdonald eval-
uation criteria, based on measurements of contrast-enhancing
lesions. It is generally assumed that it would be preferable to
have an objective measure of nonenhancing, recurrent tumor,
but the opinion of the response assessment in the neuro-
oncology (RANO) working group is that this is not possible
at the present time due to limitations of technology [26].
Unfortunately, the evaluation of the response based on the
MRI could be misleading, and for this reason, we included the
measurement of the nonenhancing tumor, changes in the
patient’s clinical condition, as well as PFS and OS. It is
generally accepted, although not ideal, that the use of overall
survival is the most reliable variable [1].
The results of this study compare favorably to the other
trials in patients with RPDIPG. The survival data in most of
these trials are nonexistent simply because patients do not
usually survive more than 6 months. Contrary to the other
studies, our PFS at 6 months is 35.3 % and overall survival
from the treatment start at 1 year is 29.4 % and approxi-
mately 11.8 % at 2 years. Even at 15 years, the overall
survival is approximately 5.9 % (patient was diagnosed with
pilocytic astrocytoma and had tumor involving 72 % of
pons at the baseline). The quality of survival is excellent
and median KPS at the conclusion of treatment increased to
80. There are no chronic adverse events, and the moderate
percentages of serious acute toxicities reported are
manageable.
Conclusions
The treatment of brainstem gliomas poses the greatest chal-
lenge for pediatric neuro-oncologists. This small phase II
study of ANP A10 and AS2-1 reports encouraging CR and
PR in recurrent pediatric DIPG with promising survival data.
Additional phase II studies of ANP in pediatric high-grade
glioma and brainstem glioma as well as astrocytoma and optic
pathway glioma have been completed and are being prepared
for publication.
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